Rezvan Yazdian–Robati - Department of Pharmaceutical Biotechnology, School of Pharmacy, Mashhad University of Medical Sciences, Mashhad, Iran
Homa Ahmadi - Department of Pharmacodynamics and Toxicology, School of Pharmacy, Mashhad University of Medical Sciences, Mashhad, Iran
Maryam Matbou Riahi - Department of Medical Biotechnology, School of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran
Parisa Lari - Department of Pharmacodynamics and Toxicology, School of Pharmacy, Mashhad University of Medical Sciences, Mashhad, Iran
Seyed Amir Aledavood - Cancer Research Center, Department of Radiation oncology, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran
Marzieh Rashedinia - Department of Pharmacology and Toxicology, School of Pharmacy, Shiraz University of Medical Sciences, Iran
Khalil Abnous - Pharmaceutical Research Center, School of Pharmacy, Mashhad University of Medical Sciences, Mashhad, Iran
Mohammad Ramezani - Nanotechnology Research Center, Department of Biotechnology, School of Pharmacy, Mashhad University of Medical Sciences, Mashhad Iran

Objective(s): Ranking as the sixth commonest cancer, esophageal squamous cell carcinoma (ESCC) represents one of the leading causes of cancer death worldwide. One of the main reasons for the low survival of patients with esophageal cancer is its late diagnosis. Materials and Methods: We used proteomics approach to analyze ESCC tissues with the aim of a better understanding of the malignant mechanism and searching candidate protein biomarkers for early diagnosis of esophageal cancer. The differential protein expression between cancerous               and normal esophageal tissues was investigated by two-dimensional polyacrylamide gel electrophoresis (۲D-PAGE). Then proteins were identified by matrix-assisted laser desorption/ ionization tandem time-of-flight mass spectrometry (MALDI-TOF/TOF-MS) and MASCOT web based search engine. Results:We reported ۴ differentially expressed proteins involved in the pathological process of esophageal cancer, such as annexinA۱ (ANXA۱), peroxiredoxin-۲ (PRDX۲), transgelin (TAGLN) andactin-aortic smooth muscle (ACTA۲). Conclusion: In this report we have introduced new potential biomarker (ACTA۲). Moreover, our data confirmed some already known markers for EC in our region.

Annexin, Actin-aortic smooth muscle Esophageal cancer, Proteomics, Peroxiredoxin, Transgelin, Two-dimensional-electrophoresis (۲D)